Merck, Inc.

🇵🇭Philippines

Country: 🇵🇭Philippines

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

Phase 3

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: pembrolizumab
Drug: regorafenib
Drug: TAS-102 (trifluridine and tipiracil)
Drug: lenvatinib

First Posted Date: 2021-03-01

Last Posted Date: 2024-10-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 480

Registration Number: NCT04776148

Locations: 🇨🇦
NSHA-QEII Health Sciences Centre-Dickson Bldg-Dept. of Medical Oncology ( Site 0200), Halifax, Nova Scotia, Canada
🇯🇵
Shizuoka Cancer Center ( Site 1706), Nagaizumi, Shizuoka, Japan
🇩🇰
Herlev and Gentofte Hospital-Department of Oncology ( Site 0704), Copenhagen, Hovedstaden, Denmark

and more 92 locations

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

Phase 3

Active, not recruiting

Conditions: HIV-1 Infection

Interventions: Drug: MK-8591A

First Posted Date: 2021-03-01

Last Posted Date: 2024-11-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 2000

Registration Number: NCT04776252

Locations: 🇺🇸
One Community Health ( Site 0045), Sacramento, California, United States
🇺🇸
Whitman-Walker Institute ( Site 0039), Washington, District of Columbia, United States
🇺🇸
Georgetown University Medical Center-Clinical Trials Unit Division of Infectious Diseases ( Site 002, Washington, District of Columbia, United States

and more 90 locations

Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

Phase 3

Completed

Conditions: Papillomavirus Infections

Interventions: Biological: 9vHPV vaccine

First Posted Date: 2021-02-26

Last Posted Date: 2024-05-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 312

Registration Number: NCT04772534

Locations: 🇯🇵
Motomachi Pediatric Clinic ( Site 6606), Sapporo, Hokkaido, Japan
🇯🇵
Ohigesenseino Kodomo Clinic ( Site 6607), Sapporo, Hokkaido, Japan
🇯🇵
Fukui General Hospital ( Site 6614), Fukui, Japan

and more 9 locations

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infection

Interventions: Biological: Clesrovimab
Drug: Placebo

First Posted Date: 2021-02-23

Last Posted Date: 2024-07-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 3632

Registration Number: NCT04767373

Locations: 🇺🇸
Children's Clinic of Jonesboro, PA ( Site 0058), Jonesboro, Arkansas, United States
🇺🇸
Senders Pediatrics ( Site 0062), Cleveland, Ohio, United States
🇺🇸
UPMC Children's Hospital of Pittsburgh - Primary Care Center - Oakland ( Site 0043), Pittsburgh, Pennsylvania, United States

and more 214 locations

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Phase 2

Active, not recruiting

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Biological: Pembrolizumab/Quavonlimab
Drug: Lenvatinib
Biological: Pembrolizumab

First Posted Date: 2021-02-05

Last Posted Date: 2023-11-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 110

Registration Number: NCT04740307

Locations: 🇺🇸
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - GI and Immunology ( Site 0013), Baltimore, Maryland, United States
🇨🇭
CHUV (centre hospitalier universitaire vaudois) ( Site 0333), Lausanne, Vaud, Switzerland
🇪🇸
Hospital Universitario Central de Asturias-Hepatology ( Site 0309), Oviedo, Asturias, Spain

and more 37 locations

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Phase 3

Active, not recruiting

Conditions: Lung Neoplasms
Non-Small-Cell Lung Carcinoma

Interventions: Biological: Pembrolizumab/Vibostolimab
Biological: Pembrolizumab

First Posted Date: 2021-02-04

Last Posted Date: 2024-11-08

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1264

Registration Number: NCT04738487

Locations: 🇺🇸
Boca Raton Regional Hospital ( Site 0004), Boca Raton, Florida, United States
🇺🇸
Illinois Cancer Care ( Site 0026), Peoria, Illinois, United States
🇺🇸
Mercy Research - David C. Pratt Cancer Center ( Site 0025), Saint Louis, Missouri, United States

and more 185 locations

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Phase 3

Active, not recruiting

Conditions: Carcinoma, Renal Cell

Interventions: Biological: Pembrolizumab
Biological: Pembrolizumab/Quavonlimab
Drug: Belzutifan
Drug: Lenvatinib

First Posted Date: 2021-02-03

Last Posted Date: 2024-11-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1653

Registration Number: NCT04736706

Locations: 🇺🇸
Hartford Hospital ( Site 0024), Hartford, Connecticut, United States
🇺🇸
Cedars Sinai Medical Center ( Site 0027), Los Angeles, California, United States
🇺🇸
New England Cancer Specialists ( Site 0082), Scarborough, Maine, United States

and more 259 locations

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Phase 2

Completed

Conditions: Pulmonary Arterial Hypertension
Hypertension, Pulmonary

Interventions: Drug: Placebo to MK-5475
Drug: MK-5475

First Posted Date: 2021-02-01

Last Posted Date: 2024-11-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 168

Registration Number: NCT04732221

Locations: 🇨🇦
University Health Network - Toronto General Hospital ( Site 0104), Toronto, Ontario, Canada
🇦🇷
Hospital Universitario Austral ( Site 0138), Pilar, Buenos Aires, Argentina
🇩🇪
Thoraxklinik Heidelberg gGmbH am Universitaetsklinikum Heidelberg ( Site 0276), Heidelberg, Baden-Wurttemberg, Germany

and more 88 locations

Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

Phase 1

Completed

Conditions: Alzheimer's Disease
Mild Cognitive Impairment

Interventions: Drug: Placebo
Drug: Donepezil

First Posted Date: 2021-01-29

Last Posted Date: 2024-10-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 44

Registration Number: NCT04730635

Locations: 🇺🇸
Velocity Clinical Research, Hallandale Beach ( Site 0013), Hallandale Beach, Florida, United States
🇦🇺
Royal Adelaide Hospital-CALHN Memory Trials ( Site 0031), Adelaide, South Australia, Australia
🇺🇸
Insight Clinical Trials ( Site 0020), Beachwood, Ohio, United States

and more 7 locations

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Phase 2

Recruiting

Conditions: Non-Hodgkins Lymphoma
Hematologic Malignancies
Waldenstroms Macroglobulinaemia
Chronic Lymphocytic Leukaemia

Interventions: Drug: Nemtabrutinib

First Posted Date: 2021-01-28

Last Posted Date: 2024-12-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 490

Registration Number: NCT04728893

Locations: 🇨🇳
Guangxi Medical University - Liuzhou Renmin Hospital ( Site 2817), Liuzhou, Guangxi, China
🇨🇳
The Second Affiliated Hospital of Chongqing Medical University ( Site 2825), Chongqing, Chongqing, China
🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio, Tianjin, Tianjin, China

and more 118 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy